gastrointestinal stromal tumor (gist,...
TRANSCRIPT
![Page 1: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/1.jpg)
Gastrointestinal Stromal Tumor(GIST, 위장관 기질 종양)
강윤구 / 류민희 / 류백렬
서울아산병원 종양내과서울아산병원 종양내과
![Page 2: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/2.jpg)
What is GIST ?
• Formerly defined as sarcoma (smooth muscle Tm y (or neural Tm) ~ 1990s
• Paradigm for molecular targeted therapy in solid TmParadigm for molecular targeted therapy in solid Tm• The most common mesenchymal tumor of GI tract• Arising from interstitial cell of Cajal (pacemaker for• Arising from interstitial cell of Cajal (pacemaker for
peristaltic contraction)P th ti ll d i b ti ti t ti i• Pathogenetically driven by activation mutations in KIT or PDGFRA
![Page 3: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/3.jpg)
Landmark Discoveries in GISTLandmark Discoveries in GIST
279:577-580, 1998
299:708-710, 2003
![Page 4: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/4.jpg)
Landmark Trial in GISTLandmark Trial in GISTwith Glivec
Demetri et al. NEJM 2002
![Page 5: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/5.jpg)
세포막의 KIT 및 PDGFRA 단백세포막의 KIT 및 PDGFRA 단백
− Extracellular domain (EC)−5개의 immunoglobulin− 정상 리간드 부착 부위
Transmembrane domain
Tyrosine kinase domain I (TKI)
Juxtamembrane domain (JM): Regulator
(ATP binding pocket)
Tyrosine kinase domain II (TKII)(Kinase activation loop)
![Page 6: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/6.jpg)
Mechanisms of KIT Activation in GIST
RegulatorRegulator
Normal GIST Hirota et al. Science 1998Kitamura et al. Mutation Res 2001
![Page 7: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/7.jpg)
KIT and PDGFRA Mutations in GISTKIT and PDGFRA Mutations in GIST
KIT PDGFRAKIT PDGFRA
Asan Medical Center
Total 87.4% 80.4%
Cell membraneExon 9 (11%) 6.2%
Cell membraneExon 12 (0.9%)Exon 14 (0.3%)
Exon 11 (67.5%)Exon 13 (0.9%)
70.6%0%
0%0%
Exon 18 (6.3%)
( )
Exon 17 (0.5%) 0.5% 3.1%
Heinrich et al. Hum Pathol 2002 Kim et al. Clin Cancer Res 2004
![Page 8: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/8.jpg)
GIST: EpidemiologyGIST: Epidemiology• Incidence: 10 20 / million• Incidence: 10 – 20 / million• Median age: 55 – 65• Gender: M >/= F• Malignant: 20 – 30%Malignant: 20 30%• Sites
St h 60 70%– Stomach: 60 – 70%– Small intestine: 20 – 30%– Colon & rectum: 5%– Esophagus: < 5%– Omentum & mesentery: rare
![Page 9: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/9.jpg)
Diagnosis of GISTDiagnosis of GIST
• Primary tumor in abdominal cavity: GI tract, peritoneump
![Page 10: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/10.jpg)
Diagnosis of GISTDiagnosis of GIST
• Primary tumor in abdominal cavity: GI tract, peritoneump
• Characteristic histologic features
Spindle cell (70%) Mixed type (10%)Epithelioid cell (20%)
![Page 11: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/11.jpg)
Diagnosis of GISTDiagnosis of GIST
• Primary tumor in abdominal cavity: GI tract, peritoneump
• Characteristic histologic features
• Immunohistochemistry– If CD117(+) in cytoplasm: diagnosis made
![Page 12: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/12.jpg)
Diagnosis of GISTDiagnosis of GIST
• Primary tumor in abdominal cavity: GI tract, peritoneump
• Characteristic histologic features
• Immunohistochemistry– If CD117(-); 4-5%
: should be CD34(+), Desmin(-?), S100(-)• DNA seqencing of Kit exon 11, 9, 13, 17, and
PDGFRA exon 12, 18 – If mutation(+), diagnosis made
![Page 13: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/13.jpg)
St i f GISTStaging of GIST
No specific staging system Localized ? Resectable ? Localized ?, Resectable ? Abdomen / pelvis dynamic CT scan
![Page 14: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/14.jpg)
St i f GISTStaging of GIST
• Rare metastasis to extraabdominal organs• PET scan is rarely neededPET scan is rarely needed
![Page 15: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/15.jpg)
Risk Stratification of GIST
Miettinen et al, Semin Diagn Pathol 2006
![Page 16: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/16.jpg)
Conventional Tx of GIST• Surgery
– The only curative approach– Complete gross resection is essential, but wide resection
margin or routine lymphadenectomy is not necessary
• Radiation– Occasionally used for symptom palliation
• Chemotherapy– Doxorubicin - containing regimens– 5% response in GIST (ASCO 2000)
![Page 17: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/17.jpg)
Targeted therapy for GISTTargeted therapy for GIST
![Page 18: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/18.jpg)
I ti ib M l t Gli GlImatinib Mesylate: Glivec, GleevecSmall Molecule Tyrosine Kinase Inhibitory
C H N O•CH SOC29H31N7O•CH4SO3
MW 589.7
Class: Phenylaminopyrimidines
Druker et al. Nat Med 1996
![Page 19: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/19.jpg)
KIT / PDGFRA 단백을 통한 세포 내 신호전달KIT / PDGFRA 단백을 통한 세포 내 신호전달
Substrate
Effector
TK domains
PP PADP P
PATP
Imatinib
PP PATP 신호전달
Savage and Antman. N Engl J Med 2002Scheijen and Griffin. Oncogene 2002
![Page 20: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/20.jpg)
Imatinib: Target SelectivityImatinib: Target Selectivity
Kinase IC50 [
Abl 0 1 0 3
Kinase IC50 [
Flt 3 10v-Abl 0.1-0.3Bcr-Abl(p210) 0.25
Flt-3 >10c-Fms and v-Fms >10
Bcr-Abl(p185) 0.25TEL-Abl 0.35
EGF receptor >100c-erbB2 >100
c-Kit 0.1PDGF receptor 0.1
Insulin receptor >100IGF-I receptor >100
TEL-PDGF receptor 0.15 v-Src >10JAK-2 >100
Druker et al. Nat Med 1996
![Page 21: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/21.jpg)
Imatinib for GIST: Pivotal Phase II Trial
Imatinib mesylate
(400 mg/d)
Metastatic or unresectable GIST (N=147)
PD Continue to treat as long
as benefit(N 147) as benefit
Imatinib mesylate (600 mg/d)
Demetri et al. NEJM 2002
![Page 22: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/22.jpg)
Imatinib for GIST: Pivotal Phase II Trial
Demetri et al. NEJM 2002
![Page 23: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/23.jpg)
Improved Survival with ImatinibImproved Survival with ImatinibCompared with Historical Conventional Chemotherapy Data
100
60
80
(%)
Imatinib (pooled 400 mg + 600 mg)
40
60
urvi
val (
20
Su
SWOG S8616/S9627
0 1 2 3 4 50
Years after registrationg
Blanke et al. 2004 ASCO GI Cancers Symposium
![Page 24: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/24.jpg)
What is Optimal Dose ofWhat is Optimal Dose of Imatinib ?
![Page 25: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/25.jpg)
Phase I Study of Imatinib- EORTC -- EORTC -
400 mg qd 300 mg bid 400 mg bid 500 mg bid(n=8) (n=8) (n=18) (n=8)(n=8) (n=8) (n=18) (n=8)
DLT Gr III Nausea (3)G III d (1)Gr III edema (1)Gr III dyspnea (1)
Mean DI 98% 89% 89% 80%
Lancet 2001:1421Eur J Cancer 2002:S83
![Page 26: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/26.jpg)
Phase III Trials of 400 mg/d vs 800 mg/dg g: EORTC 62005 and US Intergroup S0033
Imatinib mesylate
(400 mg/d)
Metastatic or unresectable GIST
Followfor
PFS
PDPFS
Imatinib mesylate (800 mg/d)
Benjamin et al. Proc Am Soc Clin Oncol 2003. Abstract 3271Rankin et al. Proc Am Soc Clin Oncol 2004. Abstract 9005Verweij et al. Proc Am Soc Clin Oncol 2003. Abstract 3272
![Page 27: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/27.jpg)
800 mg/d was NOT better than 400 mg/d g g
![Page 28: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/28.jpg)
800 mg/d was NOT better than 400 mg/d g gEORTC 62005 US Intergroup S0033
PFS
OS
Verweij et al. Lancet 2004 Blanke et al. J Clin Oncol 2008
![Page 29: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/29.jpg)
Pivotal Phase II Trial of Imatinib for GIST:Pivotal Phase II Trial of Imatinib for GIST: Long-Term Results
• 84% of patients showed a clinical benefit– 68% PR/CR
– 16% stable disease (SD)– 16% stable disease (SD)
• Time to Response: 0.8 – 39 mos (median 2.7 mos)
• Median duration of response: 29 mos
M di ll i l (OS) 57• Median overall survival (OS): 57 mos
• No difference between doses of 400 and 800 mg/d
Blanke et al. JCO 2008
g
![Page 30: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/30.jpg)
Any difference of imatinib efficacy among the genotypes
f GIST ?of GIST ?
![Page 31: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/31.jpg)
Response to Imatinib by Genotypep y yp(Pivotal phase II trial)
Blanke, et al. 2006 ASCO GI Cancer Symposium
![Page 32: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/32.jpg)
Overall Survival by Genotype(Pivotal phase II trial)
Blanke, et al. 2006 ASCO GI Cancer Symposium
![Page 33: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/33.jpg)
MetaGISTPrognostic value of Mutation StatusProgression-Free Survival Overall Survival
708090
100
708090
100
30405060
3040506070
0 1 2 3 4 50
1020
2 50 1 3 40
1020
KIT exon 11 mutants – KIT exon 9 mutants – Wild types - Other
Years Years
Median PFS (months) 26 / 13 / 16 / 11
3-year estimate (%) 38 / 11 / 27 / 9
Median OS (months) 60 / 31 / 43 / 34
3-year estimate (%) 69 / 44 / 57 / 46
Van Glabbeke # 10004
![Page 34: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/34.jpg)
Continuous Development ofContinuous Development of Resistance after Imatinib Treatment
Imatinib 400 mgTwice daily
100y
Once daily80
PFS
(%) 60
40P 40
20
00 3 6 9 12 15 18 21 24 27 30
Verweij J et al. Lancet 2004
Time (months)
![Page 35: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/35.jpg)
What can we doWhat can we do after failure of Imatinib ?after failure of Imatinib ?
![Page 36: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/36.jpg)
T t t ft f il f i ti ibTreatment after failure of imatinib
Focal progression– Local ablation: Surgery, RFA, Chemoembolization
![Page 37: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/37.jpg)
T t t ft f il f i ti ibTreatment after failure of imatinib
Focal progression– Local ablation: Surgery, RFA, Chemoemolization
General progression General progression
![Page 38: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/38.jpg)
Mechanism of Resistance
Lack of Imatinib relative to KIT/PDGFRA Lack of Imatinib relative to KIT/PDGFRA
- KIT/PDGF 수용체의 과발현KIT/PDGF 수용체의 과발현
- 글리벡의 체내 분포의 변화
Acquisition of Resistant Mutation of Receptor
Activation of other pathways
![Page 39: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/39.jpg)
T t t ft f il f i ti ibTreatment after failure of imatinib
Focal progression– Local ablation: Surgery, RFA, Chemoemolization
General progression General progression– Dose escalation
![Page 40: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/40.jpg)
Imatinib Plasma Level Correlates with TTP after Treatment (Pivotal phase II trial)
Demetri et al. ASCO-GI 2008
![Page 41: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/41.jpg)
MetaGISTPredictive value of Genotype: PFS
Median PFS (months) 6 / 19
KIT exon 9 mutants
80
90
100
Median PFS (months) 6 / 19
3-year estimate (%) 5 / 17
P value (logrank test) 0.01760
70
80
40
50
60
Kit exon 9 mutatnt800 mg
20
30
800 mg400 mg
0 1 2 3 4 50
10
0 1 2 3 4 5
Years
Van Glabbeke # 10004
![Page 42: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/42.jpg)
![Page 43: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/43.jpg)
T t t ft f il f i ti ibTreatment after failure of imatinib
Focal progression– Local ablation: Surgery, RFA, Chemoembolization
General progression General progression– Dose escalation– Other TKIs
![Page 44: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/44.jpg)
Sunitinib
H3CO
N
CH3
CH3
NF
H3C
CH3
NH
N CH3
NH
OH
F
VEGFR-2VEGFR-1
VEGFR-3
PDGFR-α
CSF-1RPDGFR-β
VEGFR-3KITFLT3
Mendel et al. Clin Cancer Res 2003
![Page 45: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/45.jpg)
Ph III T i l f S iti ibPhase III Trial of Sunitinib in Imatinib-resistant/-intolerant GIST
Conducted at 56 sites in Europe, USA, Australia and Asia (Singapore)
Sunitinib (n=243)Continue aslong as clinicalSunitinib
(S iti ib
50 mg/day, 4 weeks on, 2 weeks offImatinib-refractory or -intolerant GIST
Randomization2:1
long as clinical benefit
Sunitinib
(Sunitinib:placebo) Placebo (n=118)
-intolerant GISTpatients
PlaceboCross over tosunitinib atprogression
4 weeks on, 2 weeks offprogression
Demetri et al. Lancet 2006
![Page 46: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/46.jpg)
Ti t P iTime to Progression
Demetri et al. Lancet 2006
![Page 47: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/47.jpg)
Other TKIs in Clinical TrialsOther TKIs in Clinical TrialsDrug Targets Phase ResultsDrug Targets Phase Results
Nilotinib(AMN 107)
BCR-ABL, KIT, PDGFR
III(1st 2nd
1st and 2nd line trials on going 3rd line trial finished(AMN-107) PDGFR (1st, 2nd,
3rd line)going, 3 line trial finished
Masitinib KIT, PDGFR, Lyn III On going, , y g g
Vatalanib(PTK-787)
KIT, PDGFR, VEGFRs,
II 13% PR+53% SD in 15 imatinib-resist 1)
Sorafenib KIT, PDGFR, VEGFRs, RAF,
FLT3 RET
II 13% PR+ 58% SD in 24 imatinib/sunitinib-resist 2)
FLT3, RETDasatinib
(BMS-354825)Src/Abl, KIT,
PDGFRII
(1st line)On going
1) Joenssu et al. Ann Oncol 20072) Nimeiri et al. GI-ASCO 2008
( ) (1 line)
![Page 48: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/48.jpg)
Future strategies after failure of imatinib
Combinations of TKIs targeting KIT / PDGFRA
Destruction or downregulation of KIT / PDGFRA
Inhibition of downstream targets of KIT / PDGFRAg
![Page 49: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/49.jpg)
연구중인 약제들연구중인 약제들
Inhibit KIT production Destroy KIT
• Transcription inhibitorsFlavopiridol (CDK inhibitor):
• HSP90 inhibitorsKIT/PDGFRA is one of the– Flavopiridol (CDK inhibitor):
– phase I trial of flavopiridol + doxorubicin for sarcoma
– KIT/PDGFRA is one of the client proteins of HSP90 which maintains the conformation and activity ofconformation and activity of specific proteins in the cell
– IPI-504: phase III trial– CNF2024, 17-DMAG, KOS-
1022 : in phase I trials for1022 : in phase I trials for solid tumors
– 17AAG: in phase I, II trials f t tfor many tumor types
![Page 50: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/50.jpg)
I hibit KIT d t i liT t
Inhibit KIT downstream signaling Targets
– PI3K– PKC theta– AKT: perifosine: AKT inhibitor in phase II trials in p p
combination: glivec + perifosine or sutent + perifosine
– mTOR: phase I/II tiral of RAD001 + glivec in underway in GIST
• Other mTOR inhibitors: Rapamune, CCI779, AP23573– Bcl-2: genasense(antisense) in phase II trial in
combination with glivec
![Page 51: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/51.jpg)
C l iConclusions400 /d f i ti ib i th t d d 1st li 400 mg/d of imatinib is the standard 1st line treatment for metastatic or recurrent GISTs.– Dose adjustment with plasma drug monitoring– Nilotinib and masitinib are challenging
Dose escalation or switching to sunitinib is the standard second line treatment after failure of standard dose imatinib.– Nilotinib is challenging for dose escalation of imatinib
New agents for novel targets are urgently needed for the treatment after failure of both imatinib and sunitinib.
![Page 52: Gastrointestinal Stromal Tumor (GIST, 위장관기질종양kaim.or.kr/pds/files/hmo/201007_03.pdf · 2016-12-27 · Pivotal Phase II Trial ofPivotal Phase II Trial of Imatinib for](https://reader033.vdocuments.site/reader033/viewer/2022050314/5f7712aed8ca89684c7aaaf2/html5/thumbnails/52.jpg)